Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to spearhead the medical cannabis market in the United Kingdom by successfully attaining, for the first time, full reimbursement by the NHS of costs associated to cannabis-based medication and clinic fees for a patient enrolled in Zerenia™ Clinics UK. The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.
This ground-breaking step validates Khiron’s scientific and data-driven approach to demonstrate the efficacy, safety and cost-effectiveness of CBMPs on the management of chronic conditions such as pain and anxiety. The Company, who continues to train doctors on the prescription of CBMPs, will be presenting its real-world evidence (RWE) at the upcoming International Congress on Clinical Trials on Cannabis to an international audience of medical doctors in London’s Canary Wharf on mid-February.
Franziska Katterbach, President of Khiron Europe, comments: “There is huge demand for medicinal cannabis in the UK. More than 1.4 million British self-medicate illegally with cannabis, half of whom medicate every day, with a total spend on illicit cannabis is an estimated £2.6 billion every year. On top of that, the estimated wait times for NHS specialist consultations range drastically, but in certain areas can be up to nine months. We are prepared to work with the NHS and provide our outstanding clinical resources, medical cannabis products and certified training tools to decrease wait times for patients and ensure access to life changing medication. Having a route for patient reimbursement for cannabis-based medicinal products is an important pillar of our global strategy which we just finally achieved with mandatory reimbursement in Colombia.”
About Khiron Life Sciences Corp.
Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Germany, the United Kingdom, Switzerland, Peru, and Brazil. The Company is led by its co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors.
Visit Khiron online at https://investors.khiron.ca.